Study of MLN8237 in Combination With Irinotecan and Temozolomide
Trial ID or NCT#
Status
Purpose
The goal of the first part of this clinical trial (Phase I portion) is to study the side effects, drug breakdown (pharmacokinetics), and dosing of the drug MLN8237 when added to standard chemotherapy drugs, irinotecan and temozolomide. The goal of the second part of this clinical trial (Phase II portion) is to learn how many children and young adults show improvements in their neuroblastoma when treated with the combination of MLN8237, irinotecan, and temozolomide.
Official Title
Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Eligibility Criteria
Contact us to find out if this trial is right for you.
Contact
Pediatric Hematology/Oncology
650-723-5535
View on ClinicalTrials.gov